"Hydrazones" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds of the general formula R:N.NR2, as resulting from the action of hydrazines with aldehydes or ketones. (Grant & Hackh's Chemical Dictionary, 5th ed)
Descriptor ID |
D006835
|
MeSH Number(s) |
D02.442.288
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Hydrazones".
Below are MeSH descriptors whose meaning is more specific than "Hydrazones".
This graph shows the total number of publications written about "Hydrazones" by people in this website by year, and whether "Hydrazones" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2007 | 0 | 1 | 1 |
2009 | 1 | 0 | 1 |
2010 | 0 | 1 | 1 |
2012 | 0 | 1 | 1 |
2013 | 2 | 0 | 2 |
2016 | 2 | 0 | 2 |
2017 | 1 | 0 | 1 |
2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hydrazones" by people in Profiles.
-
Use of Levosimendan in Patients with Pulmonary Hypertension: What is the Current Evidence? Drugs. 2023 Feb; 83(3):195-201.
-
Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery. N Engl J Med. 2017 05 25; 376(21):2032-2042.
-
Development of Allosteric Hydrazide-Containing Class I Histone Deacetylase Inhibitors for Use in Acute Myeloid Leukemia. J Med Chem. 2016 11 10; 59(21):9942-9959.
-
Levosimendan in patients with left ventricular systolic dysfunction undergoing cardiac surgery on cardiopulmonary bypass: Rationale and study design of the Levosimendan in Patients with Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass (LEVO-CTS) trial. Am Heart J. 2016 Dec; 182:62-71.
-
Novel di-tertiary-butyl phenylhydrazones as dual cyclooxygenase-2/5-lipoxygenase inhibitors: synthesis, COX/LOX inhibition, molecular modeling, and insights into their cytotoxicities. Bioorg Med Chem Lett. 2014 Jan 01; 24(1):317-24.
-
Effect of levosimendan on survival and adverse events after cardiac surgery: a meta-analysis. J Cardiothorac Vasc Anesth. 2013 Dec; 27(6):1224-32.
-
The myosin motor Myo1c is required for VEGFR2 delivery to the cell surface and for angiogenic signaling. Am J Physiol Heart Circ Physiol. 2013 Mar 01; 304(5):H687-96.
-
Role of calcium and ROS in cell death induced by polyunsaturated fatty acids in murine thymocytes. J Cell Physiol. 2010 Nov; 225(3):829-36.
-
Amphiphilic multi-arm-block copolymer conjugated with doxorubicin via pH-sensitive hydrazone bond for tumor-targeted drug delivery. Biomaterials. 2009 Oct; 30(29):5757-66.
-
Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G. Cell. 2007 Jan 26; 128(2):257-67.